Ivermectine Zentiva

Ivermectin, the active ingredient in Ivermectine Zentiva, is an anthelmintic presented as a / for oral use. It treats parasitic infections such as onchocerciasis, strongyloidiasis, scabies, lice infestations and other helminth infections in appropriate patients.

GNH USA supplies Ivermectine Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivermectine Zentiva is used to treat parasitic diseases that affect the skin, intestines and other tissues. - Onchocerciasis: reduces microfilarial load and helps prevent blindness. - Strongyloidiasis: eliminates intestinal strongyloides infection. - Scabies: eradicates Sarcoptes scabiei infestation and relieves itching. - Lice infestations: clears Pediculus humanus capitis or corporis. - Other helminth infections: treats various nematode infections as indicated.

Ivermectine Zentiva may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea or abdominal discomfort. - Diarrhea or loose stools. - Dizziness or light‑headedness. - Itching or mild skin rash. - Headache.

Serious or Rare Side Effects: - Severe allergic reactions such as anaphylaxis. - Neurological events including seizures or altered consciousness. - Hepatotoxicity manifested by jaundice or elevated liver enzymes.

When prescribing Ivermectine Zentiva, consider the following safety measures. - Dose adjustment in hepatic impairment: consider reduced dose. - Avoid in patients with known hypersensitivity: discontinue if rash or swelling occurs. - Monitor for neurologic symptoms: report dizziness, seizures, or confusion. - Use caution in co‑infection with Loa loa: risk of severe adverse events. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Ivermectine Zentiva can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole): may increase ivermectin plasma levels. - Co‑administration with P‑glycoprotein inhibitors (e.g., verapamil): risk of toxicity.

Moderate Interactions (Monitor Closely): - Concurrent use with warfarin: monitor INR closely. - Combination with other antiparasitic agents: assess additive toxicity. - Use with CNS depressants: observe for enhanced sedation or respiratory depression.